Press "Enter" to skip to content

Study resurrects Merck's hopes for Keytruda in breast cancer

Just a few weeks ago Merck & Co was lamenting a failed trial for Keytruda in triple-negative breast cancer, but a new study has set the programme back on track. The earlier trial tested Keytruda (pembrolizumab) as a second- or third-line monotherapy for triple …Read more





Study resurrects Mercks hopes for Keytruda in breast cancer

Just a few weeks ago Merck Co was lamenting a failed trial for Keytruda in triple-negative breast cancer but a new study has set the programme back on track The earlier trial tested Keytruda
Read more

FDA approves promising drug for hardest-to-treat breast cancer

A study on 900 women pricey immunotherapy drugs Keytruda which earned 72 billion in 2018 and Opdivo 67 billion This Tecentriq combination is the first cancer immunotherapy regimen to be approved in breast cancer representing a
Read more

Eureka moment for cancer as the FDA approves first drug to target a tumors genetic traits rather than body parts

Keytruda made by Merck Co but may also appear in cancers of the breast prostate bladder pancreas thyroid gland and others Until now the FDA has approved cancer treatments based on where in the body the cancer started – for example
Read more

Please follow and like us:

Comments are closed.